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Abstract: This study examined whether deep ocean mineral (DOM) supplementation improved
high-intensity intermittent running capacity after short-term recovery from an initial bout of prolonged
high-intensity running in thermoneutral environmental conditions. Nine healthy recreational male
soccer players (age: 22 ± 1 y; stature: 181 ± 5 cm; and body mass 80 ± 11 kg) completed a graded
incremental test to ascertain peak oxygen uptake (V·O2PEAK), two familiarisation trials, and two
experimental trials following a double-blind, repeated measures, crossover and counterbalanced
design. All trials were separated by seven days and at ambient room temperature (i.e., 20 ◦C). During
the 2 h recovery period after the initial ~60 min running at 75% V·O2PEAK, participants were provided
with 1.38 ± 0.51 L of either deep ocean mineral water (DOM) or a taste-matched placebo (PLA), both
mixed with 6% sucrose. DOM increased high-intensity running capacity by ~25% compared to PLA.
There were no differences between DOM and PLA for blood lactate concentration, blood glucose
concentration, or urine osmolality. The minerals and trace elements within DOM, either individually
or synergistically, appear to have augmented high-intensity running capacity in healthy, recreationally
active male soccer players after short-term recovery from an initial bout of prolonged, high-intensity
running in thermoneutral environmental conditions.
Keywords: deep ocean minerals; soccer; football; high-intensity intermittent running; exercise
capacity; recovery
1. Introduction
Hydrothermal systems in the deep ocean have been proposed to be among the most credible
settings for the biological origins of life [1,2]. Indeed, such alkaline systems have been suggested as the
source of the evolution of primordial metabolism [1,3]. The marine environment possesses a rich pool
of bioactive ingredients with numerous purported health benefits [4]. Moreover, novel marine-based
bioactive compounds might also augment human performance, especially in those who engage in
physical activity [4]. Administration of deep ocean minerals (DOM) has previously demonstrated
positive effects on exercise performance in animal [5,6] and human models [7–9]. For example,
Hou et al. [7] reported that DOM extracted from 662 m below the ocean surface facilitated substantially
quicker recovery from a prolonged bout of exercise at 30 ◦C, which induced 3% reduction in body mass
of healthy males. More specifically, maximal oxygen uptake (V·O2MAX) increased by ~2% after 4 h
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compared to baseline with DOM, whilst it was reduced by ~11% with placebo. After 24 h, V·O2MAX
increased by ~6% compared to baseline with DOM, whilst it was ~13% lower with placebo. The authors
opined that specific elements in DOM, such as boron, magnesium and rubidium, were likely to have
contributed to the observed ergogenic effects. Interestingly, using a similar protocol, Stasiule et al. [9]
reported comparable differences in aerobic capacity of healthy females 4 h after supplementation with
(deep) mineral water (DMW) extracted from a well at a depth of 689 m or placebo (purified tap water).
Similarly, these authors also postulated that the minerals and trace elements that constituted DMW
may have worked collaboratively to recover normal human performance [9].
Given the importance of optimising recovery for individuals who train/compete multiple times
per day with limited time between bouts of exercise [10,11], and the fact that it is presently unknown
whether DOM can improve high-intensity intermittent running capacity, which is integral to many team
sports such as soccer [12], this study examined the effects of DOM on high-intensity intermittent running
capacity in soccer players after short-term recovery from an initial bout of prolonged high-intensity
exercise in thermoneutral environmental conditions. As such, the primary performance outcome
measure for this study was high-intensity intermittent running endurance capacity with secondary
outcomes including various metabolic (i.e., blood glucose and blood lactate), anthropometric (i.e.,
body mass), and physiological (i.e., urine osmolality) markers. We hypothesised that DOM would
augment high-intensity intermittent running endurance capacity with other variables remaining similar
between treatments.
2. Results
2.1. Graded Incremental Test
At the end of the graded increment test, mean relative V·O2, heart rate (HR), ratings of perceived
exertion (RPE), and respiratory exchange ratio (RER) were 46 ± 4 mL kg min−1, 197 ± 4 beats min−1,
19.3 ± 0.7, and 1.07 ± 0.05, respectively.
2.2. Initial Fatiguing Protocol
There were no differences between the DOM and PLA trials for the time covered during the
initial running bout at 75% V·O2PEAK (58 ± 4 min vs. 58 ± 4 min, respectively; P = 1.00, r = 0) or the
subsequent intermittent running until volitional exhaustion (163 ± 53 s vs. 160 ± 52 s, respectively;
P = 0.92, d = 0.05; −0.87, 0.98). There was no interaction (P = 0.45, Pη2 = 0.1) or main effect of treatment
(P = 0.31, Pη2 = 0.1) for HR during the bout of running at 75% V·O2PEAK. However, there was a main
effect for time (P < 0.001, Pη2 = 0.8; Table 1). There was no interaction (P = 0.23, Pη2 = 0.2) or main effect
of treatment (P = 0.09, Pη2 = 0.3) for RPEL during the bout of running at 75% V·O2PEAK, although there
was a main effect for time (P < 0.001, Pη2 = 0.9; Table 1). There was no interaction (P = 0.09, Pη2 = 0.2)
or main effect of treatment (P = 0.09, Pη2 = 0.3) for RPEO during the running at 75% V·O2PEAK; however,
there was a main effect for time (P < 0.001, Pη2 = 0.9; Table 1).
2.3. Post-Recovery Protocol
All participants completed 20 min post-recovery running at 75% V·O2PEAK for both experimental
trials. There were no interactions (P = 0.60, Pη2 = 0.1; P = 0.95, Pη2 = 0.01; P = 0.94, Pη2 = 0.02) or main
effects of treatment (P = 0.61, Pη2 = 0.03; P = 0.69, Pη2 = 0.02; P = 0.49, Pη2 = 0.1) for HR, RPEL and
RPEO, respectively, during the 20 min running at 75% V·O2PEAK post-recovery; however, there were
main effects of time for all variables (all P < 0.001, Pη2 = 0.8; Table 2).
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Table 1. Group mean cardiovascular and perceptual data during initial ~60 min running at 75%
V·O2PEAK.
Time 10 min 20 min 30 min 40 min 50 min #,+ 60 min *,#,+
Treatment DOM PLA DOM PLA DOM PLA DOM PLA DOM PLA DOM PLA
HR (beats·min−1) 150 156 157 159 162 167 164 166 167 168 170 171
SD 10 16 9 16 8 14 9 13 7 12 8 12
RPEL 2.7 3.1 3.8 3.9 4.3 4.3 5.2 5.6 5.9 6.9 6.3 7.4
SD 1.0 1.3 1.2 1.4 1.2 1.2 2.0 1.6 2.0 1.9 1.9 1.9
RPEO 10.7 11.6 12.7 12.7 13.6 14.0 14.3 15.1 15.3 16.2 15.7 17.1
SD 2.2 1.8 1.1 1.3 1.2 0.9 1.9 1.9 2.0 2.0 2.1 2.4
DOM = deep ocean minerals; PLA = placebo; HR = heart rate; RPEL = ratings of perceived exertion localised to
the legs (0–10); RPEO = ratings of perceived exertion related to overall cardiovascular strain (6–20). * > HR vs. 10,
20, and 40 min (P < 0.02); # > RPEL vs. 10, 20, 30, and 40 min (P ≤ 0.01); and + > RPEO vs. 10, 20, 30, and 40 min
(P < 0.02).
Table 2. Group mean cardiovascular and perceptual data during 20 min running at 75%
V·O2PEAK post-recovery.
Time 5 min 10 min # 15 min * 20 min *
Treatment DOM PLA DOM PLA DOM PLA DOM PLA
HR (beats·min−1) 157 160 163 163 166 167 168 169
SD 10 11 12 13 11 12 10 11
RPEL 5.0 5.2 5.8 5.9 6.6 6.9 6.9 7.1
SD 1.5 1.2 2.2 1.4 1.9 1.5 2.2 1.5
RPEO 12.9 13.1 13.8 14.1 15.1 15.2 15.8 16.0
SD 1.4 1.3 1.4 1.5 1.8 1.2 2.4 2.1
HR = Heart rate; RPEL = ratings of perceived exertion localised to the legs (0–10); RPEO = ratings of perceived
exertion related to overall cardiovascular strain (6–20). * > values after 5 and 10 min for all variables (P ≤ 0.01).
# > values after 5 min for all variables (P < 0.05).
2.4. High-Intensity Intermittent Running Capacity Test
There was no clear order effect between Trials 1 and 2 of the high-intensity intermittent running
capacity test (1048 ± 713 s vs. 1268 ± 1103 s; P = 0.21, r = 0.4). In contrast, DOM increased exercise
capacity by 56% (1411 ± 1157 s vs. 905 ± 520 s; P = 0.038, r = 0.7) compared to PLA (Figure 1).
Due to the variability in exercise capacity between treatments and participants, HR and perceptual
data were only analysed for the first four shuttles at 90% V·O2PEAK and at volitional exhaustion.
There was no interaction (P = 0.09, Pη2 = 0.2) or main effect of treatment (P = 0.68, Pη2 = 0.02) for
HR; however, there was a main effect for time (P < 0.001, Pη2 = 0.5) with HR greater at the end of
exercise (174 ± 7 beats min−1) compared to after 1 min (168 ± 7 beats min−1, P < 0.02) and 2 min
(169 ± 6 beats min−1, P < 0.05). Furthermore, there were no interactions (P = 0.86, Pη2 = 0.02; P =
0.09, Pη2 = 0.2) or main effects of treatment (P = 0.86, Pη2 < 0.01; P = 0.4, Pη2 = 0.09) for RPEL and
RPEO, respectively. As with HR, there were main effects of time for RPEL (P = 0.001, Pη2 = 0.6) and
RPEO (P < 0.001, Pη2 = 0.7), whereby RPEL (9.4 ± 0.7) and RPEO (19.2 ± 1.2) were greater at volitional
exhaustion compared to after 1 min (6.9 ± 1.6, 15.7 ± 2.0; P < 0.01) and 2 min (7.4 ± 1.6, 16.4 ± 2.1; P <
0.05), respectively.
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Figure 1. Individual and group mean high-intensity intermittent running capacity after consuming
deep ocean minerals (DOM) or placebo (PLA).
2.5. Urine Osmolality
There was no interaction (P = 0.18, Pη2 = 0.2) or main effect of treatment (P = 0.88, Pη2 < 0.01) or
time (P = 0.12, Pη2 = 0.3) for urine osmolality (Table 3).
Table 3. Urine osmolality (mOsm/kg−1) over time.
Time Baseline Post Initial bout of Runningat 75% V·O2PEAK
Post-Recovery Post-ExerciseCapacity
Treatment DOM PLA DOM PLA DOM PLA DOM PLA
P1 590 560 900 730 910 830 900 800
P2 420 300 920 360 660 90 600 90
P3 400 570 1090 1110 210 80 200 90
P4 590 600 230 610 780 860 760 850
P5 130 600 230 770 100 290 50 280
P6 180 430 180 350 170 40 180 20
P7 580 120 510 280 320 300 300 270
P8 180 600 540 20 20 10 20 10
P9 150 540 400 580 230 200 200 180
Mean 358 480 556 534 378 300 357 288
SD 200 168 338 321 321 326 318 320
DOM = deep ocean minerals; PLA = placebo.
2.6. Body Mass
There was an interaction for body mass (P < 0.02, Pη2 = 0.4), whereby body mass was greater
for DOM vs. PLA (80.1 ± 11.3 vs. 79.8 ± 11.2 kg, respectively; P < 0.05, d = 0.03; −0.90, 0.95) at
baseline only (Table 4). There was also a main effect for time (P < 0.001, Pη2 = 0.8), whereby body
mass was greater (all P < 0.001) at baseline (80.0 ± 10.9 kg) compared to after 60 min running at 75%
V·O2PEAK (79.3 ± 10.9 kg) after 2 h recovery (79.4 ± 11.0 kg) and at the end of the exercise capacity test
(79.3 ± 10.9 kg). There was no main effect for treatment (P = 0.84, Pη2 < 0.01).
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Table 4. Body mass (kg) over time.
Time Baseline *,#
Post Initial bout of Running
at 75% V·O2PEAK
Post-Recovery Post-ExerciseCapacity Test
Treatment DOM PLA DOM PLA DOM PLA DOM PLA
P1 90.0 90.0 89.5 89.8 89.5 90.0 88.5 90.0
P2 76.0 76.0 75.0 75.5 75.0 75.5 75.0 75.5
P3 96.0 95.0 94.5 94.5 95.0 95.0 95.0 95.0
P4 76.0 76.0 75.0 75.5 75.5 76.0 75.5 75.5
P5 66.0 66.0 65.5 65.5 65.5 65.5 65.5 65.5
P6 74.0 72.5 73.0 72.0 73.0 72.0 73.0 72.0
P7 66.0 66.0 65.0 65.5 65.0 65.5 65.0 65.5
P8 83.0 83.0 82.5 82.5 82.5 82.5 82.5 82.5
P9 94.0 94.0 93.5 93.5 93.5 93.5 93.0 93.5
Mean 80.1 79.8 79.3 79.4 79.4 79.5 79.2 79.4
SD 11.3 11.2 11.3 11.3 11.3 11.4 11.2 11.4
DOM = deep ocean minerals; PLA = placebo; * > than all other time points, P < 0.001; and # DOM > PLA, P < 0.05.
2.7. Blood Lactate
There was no interaction (P = 0.65, Pη2 = 0.07) or main effect of treatment (P = 0.74, Pη2 = 0.01) for
blood lactate; however, there was a main effect for time (P = 0.001, Pη2 = 0.6; Table 5).
Table 5. Blood lactate (top) and blood glucose (bottom) (mmol L−1) over time.
Time Baseline Post Initial bout of Runningat 75% V·O2PEAK *
Post-Recovery * Post-ExerciseCapacity Test *
Treatment DOM PLA DOM PLA DOM PLA DOM PLA
P1 1.4 1.0 2.4 2.5 2.4 1.4 1.3 1.6
P2 0.9 0.9 1.2 1.7 2.3 3.1 1.6 1.7
P3 1.0 1.1 5.4 5.6 1.5 3.2 1.9 1.6
P4 1.1 1.0 5.4 3.4 3.7 1.2 3.5 2.3
P5 0.6 0.9 1.9 3.8 1.4 1.6 1.9 1.9
P6 0.9 1.2 2.3 3.5 1.7 2.1 2.0 2.9
P7 0.7 0.6 3.8 1.4 1.1 1.7 2.3 2.6
P8 1.0 1.2 7.5 3.5 2.4 2.0 4.6 3.5
P9 0.8 1.0 1.8 2.1 1.1 1.8 1.6 2.3
Mean 0.9 1.0 3.5 3.1 2.0 2.0 2.3 2.3
SD 0.2 0.2 2.1 1.3 0.8 0.7 1.1 0.7
DOM = deep ocean minerals; PLA = placebo; and * > Baseline (P < 0.01).
Time Baseline Post Initial bout of Runningat 75% V·O2PEAK
Post-Recovery Post-ExerciseCapacity Test
Treatment DOM PLA DOM PLA DOM PLA DOM PLA
P1 4.4 3.6 5.6 4.3 4.8 4.8 5.3 4.3
P2 13.1 11.7 5.7 7.0 9.4 15.3 4.1 9.0
P3 4.6 4.6 4.3 4.2 5.5 5.7 3.9 3.8
P4 4.8 5.0 4.6 4.8 3.2 3.7 3.2 4.9
P5 3.7 4.2 2.9 3.5 4.3 6.2 3.6 2.9
P6 3.7 5.0 4.1 5.0 3.8 4.0 4.1 3.7
P7 3.3 3.1 3.1 2.9 6.0 4.6 2.5 2.4
P8 4.7 5.1 4.7 4.2 5.8 4.8 4.8 4.4
P9 4.2 4.6 3.4 4.6 3.5 5.4 3.4 5.4
Mean 5.1 5.2 4.3 4.5 5.1 6.0 3.9 4.5
SD 3.0 2.5 1.0 1.2 1.9 3.5 0.9 1.9
DOM = deep ocean minerals; PLA = placebo.
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2.8. Blood Glucose
There was no interaction (P = 0.43, Pη2 < 0.1) or main effect of treatment (P = 0.24, Pη2 = 0.2) or
time (P = 0.13, Pη2 = 0.2) for blood glucose (Table 5).
3. Discussion
Oral ingestion of DOM has previously demonstrated positive effects on exercise performance
in humans [7–9], although such benefits have been observed during exercise after recovery from
an initial bout of prolonged dehydrating exercise in the heat (i.e., 30 ◦C). Therefore, the aim of this
study was to examine whether DOM facilitated ergogenic benefits during exercise after recovery from
an initial bout of prolonged exercise in more thermoneutral conditions (i.e., 20 ◦C). In support of
our hypothesis, DOM increased high-intensity intermittent running capacity in recreationally active
soccer players at the group level by 56%. However, assuming a conservative daily variation of ~10%
for a high-intensity exercise capacity test [13], and after accounting for any potential order effects
between Trials 1 and 2 of ~20%, we suggest the minimum likely ergogenic effects after DOM at the
group level to be ~25%. In summary, oral ingestion of DOM seems likely to promote ergogenic
benefits for recreationally active soccer players after recovery from prolonged exercise in thermoneutral
environmental conditions; however, given the somewhat variable results, an individual approach to
supplementation is warranted.
In the present study, body mass was greater at baseline compared to after 60 min running at 75%
V·O2PEAK after 2 h recovery and at the end of the high-intensity intermittent exercise capacity test.
The majority of this reduction in body mass over time is most likely indicative of sweat losses. As
prolonged endurance exercise might induce an increase in magnesium (Mg) excretion via sweat and
urine [6], it is plausible that participants in the present study exhibited marked Mg losses. Additionally,
amongst several other factors such as decreases in food crop magnesium content and the availability of
refined and processed foods, the vast majority of people in modern societies are at risk for magnesium
deficiency regardless. Furthermore, a normal serum Mg level does not necessarily rule out Mg
deficiency [14]. As Mg is involved with numerous fundamental biological processes, such as energy
production, electrolyte regulation and oxygen uptake, and with evidence that marginal Mg deficiency
impairs performance and augments the negative consequences of strenuous exercise [15], it seems
likely that the high Mg concentration in DOM (Table 6) has played some role in the observed ergogenic
effects. Indeed, the mean amount of Mg consumed from DOM in the present study (~236 mg) was
~80% of the participant’s 300 mg recommended daily allowance (RDA) [16]. Moreover, a recent review
provides further support for the potential of magnesium supplementation to improve aspects related
to both aerobic and anaerobic exercise [17].
Boron (B) has been shown to boost Mg absorption, reduce levels of inflammatory biomarkers such
as high-sensitivity C-reactive protein (hs-CRP), tumour necrosis factor α (TNF-α), and interleukin 6
(IL-6), as well as contribute to the synthesis and activity of crucial biomolecules such as nicotinamide
adenine dinucleotide (NAD+; [18]). Therefore, the B in DOM could work synergistically with elevated
levels of Mg, or it could work individually through the mediation of exercise-induced inflammation
and/or through facilitating key biochemical reactions where NAD+ is crucial, such as ATP production
and calcium signalling [18]. Albeit in an older population and using a different exercise modality than
the present study, we have previously shown that DOM can mediate the post-exercise neutrophil
to lymphocyte ratio (NLR; [19]), which is associated with various cytokines including IL-6 [20].
Furthermore, both acute (one day) and chronic (seven days) B supplementation has been shown to be
tolerated well in humans with chronic supplementation displaying large reductions in inflammatory
cytokines and a large increase in free testosterone [21]. However, it should be added that the mean
dosage used in the present study (~0.74 mg) was substantially less than the acute dosage used in the
aforementioned study (10 mg; [21]), and that using similar hardness of DOM (713) to that of the present
study (704), Hou et al. [7] reported no differences in testosterone between DOM and PLA.
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Rubidium (Rb), present in all human tissues and ranging from 8 to 30 mg·kg−1 [22], has been
referred to as a ‘biological proxy’ for potassium (K+) [23]. It is well known that there is a rapid
and marked increase of extracellular K+ and considerable loss of K+ from active muscle during
high-intensity exercise. Thus, it is likely that the resultant electrical changes induced by ionic shifts
across the muscle surface membrane are principal contributors of fatigue [24]. Therefore, it is possible
that the high levels of Rb in DOM (Table 6) might proxy for K+ and facilitate a prolonged status of
optimal electrical activity and, hence, contraction in the muscle, thus delaying fatigue. Furthermore,
Rb has been found to be 49% and 34% greater in professional footballers than sedentary controls and
long-distance runners, respectively [25]. However, although Rb is associated with the K cycle, it does
not necessarily substitute for it [22,25] and, thus, other mechanisms might be responsible. Besides, Rb
has been implicated in brain function, although specific roles are yet to be identified [22,25].
In support of our hypothesis, the present study found no differences in urine osmolality between
treatments. This is in contrast to Keen et al. [8] who reported that DOM returned salivary osmolality to
baseline values approximately two-fold quicker than spring water and a carbohydrate-based sports
drink. However, a variety of methodological differences between studies are likely to explain the
observed difference. For example, the participants in the Keen et al. [8] study had exercised in the heat
to achieve approximately −3% reduction in body mass, and subsequent rehydration was based on
prescriptive rather than ad libitum intake. Furthermore, salivary osmolality demonstrates considerable
day-to-day measurement variability and in magnitude of response to hypohydration; thus, its use as a
method of assessing hydration status has been questioned [26]. However, despite differences in urine
osmolality between studies, Keen et al. [8] also reported physical performance improvement with
DOM. Ingesting DOM facilitated the greatest recovery of post-exercise knee extension peak torque,
although participants failed to fully recover baseline peak torque regardless of treatment. In contrast
to our original hypothesis, we observed a difference in body mass at baseline between DOM and
PLA. However, the difference of 0.28 kg was well below the typical daily variation of body mass
measurement in young males (0.6 kg) previously reported [27]. Thus, we do not believe differences in
body mass had any major influence on our results.
In support of our hypothesis, there were no differences in blood lactate and blood glucose between
DOM and PLA. This was similar to Wei et al. [19], who reported no differences in either metabolite
after 15 min cycling at 75% V·O2MAX. Importantly the absolute values of blood lactate after 60 min
running at 75% V·O2PEAK in the present study were similar to those observed in various other studies
examining blood lactate responses in the second half of a soccer match (3.7 to 4.7 mmol L−1; [28]),
highlighting that our protocol had a similar metabolic profile. However, with various methodological
differences between studies and a lack of other data, the influence of DOM on blood lactate and blood
glucose requires further investigation.
Arguably the most intriguing finding from the metabolic data relates to a specific participant who,
after completion of this study, was diagnosed with type I diabetes. The participant confirmed there
was a familial history of this, which was undisclosed prior to participation (P2; Table 5, bottom panel).
Strikingly, at the end of the recovery period, blood glucose had increased by 65% (+3.69 mmol L−1)
after DOM but 117% for PLA (+8.23 mmol L−1) when compared to values at the end of 60 min running
at 75% V·O2PEAK. Excluding P2, the mean increase in blood glucose between these time points was
18% and 22% for DOM and PLA, respectively. Furthermore, only part of the difference observed for
P2 might be explained by the differences between treatments of −1.39 mmol L−1 at baseline and of
+1.35 mmol L−1 after completion of 60 min running at 75% V·O2PEAK for PLA vs. DOM, respectively.
The potential of DOM to facilitate greater glucose uptake is supported by Ha et al. [29], who reported
that DOM improved glucose tolerance and suppressed hyperglycaemia via modulation of glucose
metabolism in streptozotocin-induced diabetic mice. The potential antidiabetic effects of DOM (or
derivatives of) have also been reported in various other animal models [30–32]. Furthermore, a number
of the elements contained in DOM, such as vanadium [33] and chromium [34], have also been strongly
linked to improved glucose metabolism.
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This research has a number of strengths. Firstly, we are the first to report ergogenic benefits after
oral ingestion of DOM in humans in thermoneutral environmental conditions; thus, we expand on the
potential pool of individuals who might benefit from this approach. Additionally, by incorporating
fluid consumption based on an individual participant’s preference in familiarisation trials, we feel this
provides wider applied ecological validity. This research is also not without limitation. Even though
the sample size is consistent with seminal papers in this field [7,9], we acknowledge the relative lack of
statistical power. Moreover, we acknowledge that the analysis on the type I diabetic participant is
somewhat speculative and, thus, should be treated with caution. That said, we believe it could serve
as useful initial case study data and therefore could be a translational platform to research examining
the potential effects of DOM on (dysfunctional) glucose metabolism in humans during/post exercise.
In summary, in support of our hypothesis, DOM increased high-intensity intermittent running
capacity in soccer players after short-term recovery from an initial bout of prolonged exercise at the
group level by ~25%. To date, the mechanism for this effect is unclear, and further work is required to
establish the mechanism(s) behind the ergogenic effects of DOM to maximise its potential performance
and health benefits in the wider community.
4. Materials and Methods
4.1. Participants
After reading an information sheet about the proposed research, and subsequently providing
written informed consent, nine healthy, nonelite male soccer players (age: 22 ± 1 y; stature: 181 ± 5 cm;
body mass 80 ± 11 kg; mean weekly soccer-specific training time: 134 ± 64 min (range: 40 to 240);
and mean nonsoccer-specific training time (e.g., gym/outdoor running): 37 ± 44 min (range: 0 to 90))
volunteered to participate in the study, which had received university ethical approval (reference:
S2BR2016). The experimental cohort was recruited via opportunistic and convenience sampling.
Participants were eligible if they were nonelite soccer-playing males who were healthy, free from injury,
and were between 18 and 30 years of age.
4.2. Experimental Design
Participants completed five visits to the laboratory. Firstly, they completed a graded incremental
test to ascertain peak oxygen uptake (V·O2PEAK) followed by two familiarisation trials. Using a repeated
measures, crossover, and counterbalanced design, participants then completed two experimental
trials. All trials were completed on a motorised treadmill (Mercury S, Woodway, Waukesha, WI,
USA), separated by 7 d, undertaken at ambient room temperature (i.e., ~20 ◦C), and commenced at
similar times of day (e.g., 9 am and 10 am) to minimise any potential circadian rhythmic effects on
soccer-specific endurance [35].
4.3. Pre-Experimental Procedures
Participants refrained from strenuous physical activity and alcohol for at least 24 h prior to exercise.
Participants were also requested to keep a written record of their dietary intake 24 h before their first
trial and to replicate this before all remaining trials. Participants were also asked to avoid consuming
any dietary supplements that might influence exercise (e.g., caffeine) 24 h prior to each trial. Due to the
extended washout period, participants were verbally screened for the use of beta-alanine and creatine
monohydrate supplementation. No participant was excluded from the study due to prior ingestion
of either.
On the first visit to the laboratory, the participant’s age, stature (cm), and body mass (kg) were
recorded, with only body mass being recorded on subsequent visits. One hour prior to exercise,
participants were asked to ingest 500 mL of tap water to ensure an adequate and consistent level of
hydration status [36]. Hydration status was measured via urine osmolality (Pocket Refractometer,
Atago, Tokyo, Japan) and adequate hydration was deemed as <600 mOsmol·Kg−1 [37]. If participants
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did not achieve this, they were required to slowly consume water during 15 min seated rest before being
re-tested. If urine osmolality was found to be still >600 mOsmol·Kg−1, participants were excluded
from the trial. Two participants required small amounts of water in addition to the 500 mL bolus, but
all participants were found to be adequately hydrated before each trial. A heart rate (HR) monitor
(FS3c, Polar, Finland) was subsequently attached. After 5 min seated rest, HR was recorded, and a
finger prick capillary blood sample was taken and subsequently analysed for blood lactate (BLa) and
blood glucose (BGl) concentrations (Biosen C_line, EKF Diagnostic, Magdeburg, Germany).
4.4. Graded Incremental Test
Assessment of V·O2PEAK was achieved using an incremental exercise test on a motorised treadmill
(Mercury S, Woodway, Waukesha, WI, USA). After completing an initial 5 min warm up at 8 km h−1,
participants commenced running at 9 km h−1 for 3 min. Incremental increases of 1 km h−1 were applied
every three minutes until volitional exhaustion. At the end of each stage, and upon completion of
exercise, HR was telemetrically recorded, and ratings of perceived exertion (6–20; [38]) were collected.
Expired breath-by-breath gas (Cortex, Metalyser II, Leipzig, Germany) was recorded throughout the
test and subsequently analysed for oxygen consumption (V·O2) and the respiratory exchange ratio
(RER) over the last 60 s of rest and the last 30 s of exercise.
4.5. Familiarisation Trials
After collection of initial baseline measures as previously described (i.e., body mass, HR, BLa
concentration, and BGl concentration), participants commenced a 5 min warm up on the treadmill
at 8 km h−1. Immediately after completing the warm up, participants then ran for ~60 min at a
running velocity corresponding to 75% V·O2PEAK (NB: two participants were unable to complete the
full 60 mins on their first trial; however, they repeated the exact same duration for their second trial,
hence, the mean of 58 ± 4 min vs. 58 ± 4 min reported in Section 2.2). This intensity was chosen as
the energy expenditure in soccer that has been reported to correspond with 75% maximal aerobic
power [28]. Every 15 min during exercise (e.g., 15, 30, 45, and 60 min), participants were given a 20 ml
bolus of tap water for thermal comfort. Ratings of perceived exertion based on overall cardiovascular
strain (RPEO; 6–20; [39]) and localised to the leg musculature (RPEL; 0–10; [40]) were collected every
10 min. Immediately following this, participants performed repeated 1 min intervals at a velocity
corresponding to 90% V·O2PEAK, interspersed with 1 min active recovery periods at 5 km h−1 (walking
pace), until volitional exhaustion. At the end of each 1 min interval at 90% V·O2PEAK, HR, RPEO,
and RPEL were recorded. This protocol was selected because it replicated the activity patterns and
metabolic stress of speed endurance training sessions and was therefore relevant to individuals who
competed in invasion sports such as soccer [41]. Upon completion of exercise, participants completed
2 min active recovery, after which body mass was remeasured and further urine, BLa, and BGl samples
were collected and analysed as previously indicated.
Participants subsequently recovered for 2 h in a semisupine position. During this period, they
were provided with two litres of tap water to ingest ad libitum. The mean amount consumed during
familiarisation sessions (1.38 ± 0.51 L) was subsequently used to calculate the volume of fluid provided
during experimental trials. Additionally, after 30 min recovery, participants were given a standardised
cereal bar (Nature Value™ Crunchy Oats and Honey Bar, General Mills, Uxbridge, UK) that contained
192 kcal (850 kJ) and constituted 7.2 g of fat (1.0 g saturated), 27.1 g carbohydrates (11.9 g sugar), 3.4 g
protein, and 2.4 g of fibre.
After the two-hour recovery period, further urine, BLa, and BGl samples were collected and
analysed as previously indicated. Baseline HR was then recorded prior to commencing a 5 min warm
up at 8 km h−1. Subsequently, participants then ran for 20 min at a running velocity corresponding 75%
V·O2PEAK. For our primary performance outcome measure, the same pattern of intermittent running
until volitional exhaustion (e.g., 1 min at 90% V·O2PEAK followed by 1 min active recovery at 5 km h−1)
was then completed a final time with HR, RPEO, and RPEL collected at the end of each interval at 90%
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V·O2PEAK. Upon completion of exercise, participants completed 2 min active recovery, after which
body mass was measured a final time, and further urine, BLa, and BGl samples were collected and
analysed as previously indicated. Participants were then free to leave the laboratory.
4.6. Experimental Trials
Experimental trials were identical to familiarisation trials with one exception. During recovery,
participants were provided with 1.38 ± 0.51 L of either deep ocean mineral water (DOM; PDO Biotech,
Taiwan) or a taste-matched placebo (Table 6). Treatments were administered double-blind.




Purified Water (RO) 93.25 93.65
Sucrose 6.00 6.00
Deep Ocean Mineral (DOM) Concentrate 0.40 N/A
Flavour (Grapefruit, Citrus Paradise) 0.12 0.12
Citric Acid 0.12 0.12
Concentrated Lemon Juice 0.05 0.05
Calcium Lactate 0.04 0.04
Potassium Chloride 0.02 0.02
Sodium Chloride 0.01 0.01
Key: DOM = deep ocean mineral water; PLA = placebo.
Element mg/L (Undiluted) mg/L (Diluted)
Magnesium (Mg) 42,797 170.70
Sodium (Na) 13,700 54.64
Calcium (Ca) 56 0.22
Potassium (K) 14,200 56.64
Boron (B) 135 0.54
Rubidium (Rb) 4.7 0.02
Note: Diluted = Undiluted × 0.4%; Overall hardness of DOM = 704.
4.7. Statistical Analysis
Data were analysed using IBM SPSS (v24, IBM Corp, Armonk, NY, USA). For all data, normality
(via Shapiro–Wilk’s test) and homogeneity of variance/sphericity (via Mauchly’s test) were checked
prior to choosing the appropriate statistical tests. With the exception of the exercise capacity data
(Wilcoxon Signed Ranks Test), a number of two-way (treatment, time) repeated measure ANOVAs
were subsequently conducted. If sphericity was violated, degrees of freedom were corrected using
Greenhouse-Geisser values, and Bonferroni adjusted pairwise comparisons were applied. Additionally,
Tukeys’ HSD post hoc analysis was undertaken for interactions by calculating the difference required
between means for a minimum level of P = 0.05 [42]. Data were analysed and quantified using effect
sizes (ESs) and P values (P ≤ 0.05). For ANOVA main effects and interactions, the ES was reported
as the partial η2 (Pη2). Otherwise, for normally distributed data, the ES (d) was calculated using the
difference in means divided by the pooled standard deviation (SD) of the compared values [43] with
95% confidence intervals (CI) reported and adjusted for bias [44,45]. For non-normally distributed data,
the ES (r) was calculated as Z/
√
n [46]. Unless otherwise stated, data were presented as mean ± SD.
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